All In Biotech

NDA 217006 · Otsuka

Abilify Asimtufii

Aripiprazole · Intramuscular · Atypical Antipsychotic

Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Apr 27, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

401

123 Phase 3, 18 recruiting

FAERS reports

42,627

36,055 serious, 3,410 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY ASIMTUFII is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death ( 5.1 ) ABILIFY ASIMTUFII is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

What it is approved for

From the label in effect Apr 4, 2025.

ABILIFY ASIMTUFII is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults ABILIFY ASIMTUFII is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults ( 1 ) as maintenance monotherapy treatment of bipolar I disorder in adults ( 1 )

Mechanism: The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ABILIFY ASIMTUFII · ARIPIPRAZOLE 960MG/3.2ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ABILIFY ASIMTUFII · ARIPIPRAZOLE 720MG/2.4ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.

All 401 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,434
  • off label use2,968
  • product use in unapproved indication2,295
  • drug interaction2,287
  • weight increased2,186
  • anxiety1,806
  • condition aggravated1,714
  • suicide attempt1,584
  • fatigue1,553
  • suicidal ideation1,456
  • toxicity to various agents1,429
  • nausea1,388

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200468
2005111
2006161
2007217
2008192
2009256
2010342
2011354
2012534
2013428
2014584
20151,211
20161,456
20172,955
20183,363
20193,484
20203,049
20213,704
20223,702
20234,183
20244,341
20254,314
20263,618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Abilify Asimtufii (Aripiprazole)

2024 spending

$63.1M

Beneficiaries

3,361

11,621 claims

Per beneficiary

$18,785

$1,764.24 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$13,218,818
2024$63,138,033

Part B: Abilify Asimtufii (Aripiprazole) · HCPCS J0402

2024 spending

$89K

Beneficiaries

22

45 claims

Per beneficiary

$4,054

2024 ASP limit $5.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$89,191

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,035 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.